

RECEIVED Application No. 10/659,063
CENTRAL FAX CENTER Filed: September 10, 2003
TC Art Unit: 1623
OCT 12 2006 Confirmation No.: 3827

REMARKS

The Examiner continues to reject pending claims 1-6 and 8 as obvious over von Lund et al. This rejection is traversed for the reasons given below and reconsideration is respectfully requested.

In the Office Action, the Examiner stated that the Applicants' arguments in the previous paper were not found convincing as there is no limitation "that requires the said cADPR derivative to be an agonist (see claim 1)" (emphasis added). With respect, the Applicants point out that in the relevant language of claim 1:

administering to said patient a therapeutically effective amount of a composition comprising cyclic adenosine diphosphate ribose (cADPR), or a functional analogue or derivative thereof,

the adjective "functional" modifies both nouns "analogue" and "derivative." Thus, Applicants again assert that the administered compound in the method of the invention is required to be cADPR or a compound having the *same function*, i.e., an agonist of cADPR. However, because of the Examiner's concern, claims 1 and 8 have been amended to recite "agonist" explicitly. Applicants submit that the meaning of these claims has in no way been changed by these amendments.

The Applicants' argument can be summarized as follows:

-5-

WEINCASPER, SCHURMAN,
GALANTER & LEBOVICI LLP
TEL. (617) 512-2290
FAX. (617) 451-0313

Application No. 10/659,063
Filed: September 10, 2003
TC Art Unit: 1623
Confirmation No.: 3827

- [0032], cited by the Examiner, includes a list of modulators, "such as agonists and antagonists," of CD38 enzyme activity and/or cADPR dependent responses that can be used in the Lund method and a list of treatable disorders. This second list includes both conditions where inflammation needs to be treated (as in the method of the instant invention) and conditions where inflammation needs to be induced (such as infections).
- As [0032] is not specific as to which modulator is suggested for which condition, it must be interpreted in conjunction with [0013].
- [0013], first half of the paragraph, states that CD38 antagonists may be used in the treatment of *inflammation* among other disorders.
- [0013], in the second half of the paragraph, states that agonists of CD38 should be used when the subjects are "infected with pathogenic microorganisms," i.e., a condition in which *inflammatory agents are recruited and inflammation is induced to fight the infection*.
- In Applicants' method, however, agonists are taught as useful for fighting inflammation, not as useful for inducing it.
- Thus, Lund et al. teaches the exact opposite treatment as in the Applicants' claimed method. Applicants submit that Lund et al. is a clear teaching away situation and that one of ordinary

Application No. 10/659,063
Filed: September 10, 2003
TC Art Unit: 1623
Confirmation No.: 3827

skill would never have been led to the Applicants' invention through any of the Lund et al. teachings.

• While not being bound by any theory, it is believed that these results are so different because the Applicants have based their claims on sound observation and direct testing of the effects of cADPR on inflammation itself, not on a removed effect. In contrast, Lund et al. created a totally artificial environment in their animal model by working with CD38KO mice, an environment that, from their results, clearly should not be extrapolated to clinical conditions.

The Applicants submit, therefore, that the rejection over Lund et al. has been overcome and that all claims are in condition for allowance. Such action is respectfully requested.

Application No. 10/659,063
Filed: September 10, 2003
TC Art Unit: 1623
Confirmation No.: 3827

The Examiner is encouraged to telephone the undersigned attorney to discuss any matter that would expedite allowance of the claims in the present application.

Respectfully submitted,

MITCHELL P. FINK ET AL

By: Holliday C. Heine
Holliday C. Heine, Ph.D.
Registration No. 34,346
Attorney for Applicant(s)

WEINGARTEN, SCHURGIN,
GAGNEBIN & LEBOVICI LLP
Ten Post Office Square
Boston, MA 02109
Telephone: (617) 542-2290
Telecopier: (617) 451-0313

HCH/raw
338216.1

- 8 -

WEINGARTEN, SCHURGIN,
GAGNEBIN & LEBOVICI LLP
TEL. (617) 542-2290
FAX. (617) 451-0313

PAGE 10/10 * RCVD AT 10/12/2006 4:36:30 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-2/7 * DNIS:2738300 * CSID:6176950892 * DURATION (mm:ss):02:54